Press Releases

Date Title and Summary View
Toggle Summary Neoleukin Therapeutics Announces Additions to Management Team
Leslie Aberman , Vice President, Legal Affairs and Intellectual Property Samantha Willing , Vice President, People SEATTLE , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to
View HTML
Toggle Summary Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced it has granted equity awards that were approved by the
View HTML
Toggle Summary Neoleukin Therapeutics and Aquinox Pharmaceuticals Complete Merger Transaction
Nasdaq Ticker Symbol “NLTX” to be effective Monday, August 12, 2019 SEATTLE, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the completion
View HTML
Toggle Summary Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, and Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), today announced that Jonathan G.
View HTML
Toggle Summary Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement
• Combined company capitalized with approximately $65M to develop novel immunotherapies Neoleukin is a biopharmaceutical company creating next generation immunotherapies using de novo protein design technology. • Sophisticated computational platform enables new class of de novo protein therapeutics
View HTML